Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ahmet Sevindik
Turkish drug industry association AIFD is demanding that the court cancels a government policy under which multinational companies are facing the threat of having their medicines removed from the reimbursement list unless they produce them locally.
The Turkish government plans to fix the country’s tamoxifen drug shortage problem by allowing by a local company to manufacture the product.
Koçak Farma’s launch of a biosimilar version of Lantus could encourage Sanofi to invest in local production in Turkey, especially if the originator is at risk of being left off the reimbursement list.
Turkey’s fast track medicines evaluation system is expected to play a big part in the country’s drive to get multinational companies to produce their drugs locally.
In a bid to increase local products of medical equipment and reduce costs of importing expensive devices, Turkey has introduced financial incentives to attract multinationals to set up manufacturing facilities in the country. One priority area of this initiative will be medical imaging technologies.
TR-PHARM, a Turkish affiliate of the leading Russian pharma company R-PHARM, has disclosed promising early results for clinical trials with a potential new biologic treatment for familial Mediterranean fever.